Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV

NCT02128542 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02128542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02128542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2014
Completion date
June 30, 2015
Enrollment
66 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection